Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma - Wikidata - wikimedia - TriplyDB

Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma

Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma

http://www.wikidata.org/entity/Q34549516

about

Risk based neoadjuvant chemotherapy in muscle invasive bladder cancer Integrative clinical genomics of advanced prostate cancer.Elevating the Horizon: Emerging Molecular and Genomic Targets in the Treatment of Advanced Urothelial Carcinoma Invasive Bladder Cancer: Genomic Insights and Therapeutic Promise Comprehensive assessment of cancer missense mutation clustering in protein structures Systemic, perioperative management of muscle-invasive bladder cancer and future horizons.Systemic therapy for bladder cancer finally comes into a new age.The genomic landscape of testicular germ cell tumours: from susceptibility to treatment.Phase 2 trial of the topoisomerase II inhibitor, amrubicin, as second-line therapy in patients with metastatic urothelial carcinoma.DNA Repair Pathway Alterations in Bladder Cancer.The Role of Neoadjuvant Trials in Drug Development for Solid Tumors.Molecular biology of bladder cancer.Novel molecular targets for urothelial carcinoma A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance The safety and efficacy of single-agent pemetrexed in platinum-resistant advanced urothelial carcinoma: a large single-institution experience Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial Carcinoma Gemcitabine and cisplatin neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma: Predicting response and assessing outcomes.Pharmacogenomics: Biomarker-Directed Therapy for Bladder Cancer.Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer.The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder.Urothelial carcinoma management in elderly or unfit patients.Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer Collaborating to Move Research Forward: Proceedings of the 10th Annual Bladder Cancer Think Tank.Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors.Precision medicine for advanced prostate cancer.An Epigenomic Approach to Improving Response to Neoadjuvant Cisplatin Chemotherapy in Bladder Cancer Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use SEOM Clinical Guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2016).Circulating Biomarkers in Bladder Cancer.New discoveries in the molecular landscape of bladder cancer.Nucleotide excision repair (NER) alterations as evolving biomarkers and therapeutic targets in epithelial cancers New advances in genitourinary cancer: evidence gathered in 2014.Evasion of immunosurveillance by genomic alterations of PPARγ/RXRα in bladder cancer Dose dense MVAC prior to radical cystectomy: a real-world experience.ARF Confers a Context-Dependent Response to Chemotherapy in Muscle-Invasive Bladder Cancer DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma.The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics.Systemic therapy in muscle-invasive and metastatic bladder cancer: current trends and future promises.Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset.PDK1 and SGK3 Contribute to the Growth of BRAF-Mutant Melanomas and Are Potential Therapeutic Targets.

P2860

Q26773664-5C157B87-73AD-4D35-9BE5-6D95B36C7320 Q27853170-5CFB6FA2-C258-4C5E-8B6B-3DC1A3B5E3C4 Q28084715-0D94CA66-0983-4E8C-8C56-BA5022597F8B Q28088334-7094C49E-4641-4688-A07A-9AE2DA23A032 Q28606437-6B5EBF4A-4453-4902-A9FC-47707ACFFA63 Q30240816-C36862F4-F522-4575-AEA5-BC07ADF10787 Q30249047-BF98D57B-D16C-462E-8EAD-B7CE9DA6CC86 Q30249650-F43F132B-D0B1-4642-B9D2-F8F55C70FF49 Q33426694-3C61E3B2-3583-4305-826D-0919F234BFB4 Q33607945-8E94D816-FD23-4484-B178-77CF98126E07 Q33886353-576AEAA2-5BE8-40B6-90B4-98D385FE6578 Q35266400-9342777C-97C3-46A7-B21B-F5CE1B429D9B Q35527068-7AC76114-3AC2-449B-B41B-4318BB086ED7 Q35559721-3C027FDC-7EEB-444B-8186-70BCA7E6FE9C Q35586693-3ADC88BE-AB01-4EA9-BE8E-B6431916EDCA Q35731224-AEEFC081-F0F8-4317-B617-0C81D0B2EBE6 Q35866471-3727724B-3ED5-4C53-82E5-1D02AE3AF737 Q36328010-7F422DA6-5162-4727-83C7-6AB8A7D43646 Q36608587-60847398-55C9-4D89-B9EE-92188BC3134F Q37012561-429CB563-1E29-4520-AA03-8ABA77E05890 Q37030514-B7F78E9B-195D-481C-9AED-98394213E5EF Q37053820-C9B6713B-28A5-44DA-90D1-C97CA0E92623 Q37053881-B8ED594E-DE40-4E87-A3DB-6D4B254BDC6D Q37074346-8D93879B-7048-48A5-A830-CEB4DE54F462 Q37114034-5D0B5EC2-314F-4F81-8859-81F3060C7209 Q37290684-3038F50A-8140-495F-8385-A2886A670DF6 Q37363521-88A572DE-11E7-4893-8F97-3BF89A5DE8BC Q37475193-405073E5-22A2-4BC4-8DC0-4CF2EA4B5450 Q37530401-300DB685-B38D-4CF4-9E86-0A07CA39D7FF Q37578747-8C06FFD8-7383-4CA8-A295-AC4BB8B3108B Q38259678-6ACC0295-B177-4503-9506-1AAAA20898AB Q38557894-CCE7F182-02DA-4420-9EE6-7516C29F029D Q38663576-F1257B10-2991-4BBA-A140-0D8629358624 Q38720755-223C9B76-5296-46F7-B1CF-D3BD5D9B3F21 Q38721568-319E253A-1E89-4533-BE6F-725154A860A9 Q38764205-81B46932-08A3-4DF3-A26A-919EF03B741E Q38827251-1ACE7570-AAD9-41F6-958A-F8301E76EFA5 Q38852690-BB08C690-320D-4679-A395-3F0B5D248BCD Q38862963-AF156DEF-1CF7-4DE5-8392-A0B794993A08 Q38906407-927A7756-E1D8-4BD5-925A-347718B2ADD3

P2860

Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma

http://www.wikidata.org/entity/Q34549516

description

2014 nî lūn-bûn

@nan

2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Somatic ERCC2 mutations correl ...... -invasive urothelial carcinoma

@ast

Somatic ERCC2 mutations correl ...... -invasive urothelial carcinoma

@en

Somatic ERCC2 mutations correl ...... -invasive urothelial carcinoma

@nl

type

label

Somatic ERCC2 mutations correl ...... -invasive urothelial carcinoma

@ast

Somatic ERCC2 mutations correl ...... -invasive urothelial carcinoma

@en

Somatic ERCC2 mutations correl ...... -invasive urothelial carcinoma

@nl

prefLabel

Somatic ERCC2 mutations correl ...... -invasive urothelial carcinoma

@ast

Somatic ERCC2 mutations correl ...... -invasive urothelial carcinoma

@en

Somatic ERCC2 mutations correl ...... -invasive urothelial carcinoma

@nl

P1433

Q34549516-BBC7B723-ED57-40B1-A4DC-04AE5058DE5D

P1476

Q34549516-205CA611-2077-4E24-93F0-B9B5821A7234

P2093

Q34549516-106CC038-B0B3-423C-B8E7-86F6D0B8641A

Q34549516-1A690603-89BE-4DA2-ACAF-A3A17869E97E

Q34549516-1EF90439-6D13-45DA-9B52-4F9C1CC08764

Q34549516-235A87FD-7107-4380-90C1-2D846B81DB7F

Q34549516-29D14609-26E3-4975-822C-6EBDA88CF268

Q34549516-2CC22F94-0BE1-4681-B62C-39B1E613F177

Q34549516-3314CD90-518D-4042-A9FA-FA7876226D8B

Q34549516-33B0204B-6703-41BD-A55D-5C94803AD6B3

Q34549516-6097316B-703B-463E-AEFC-4293A97E81AC

Q34549516-6F638048-D73A-4097-8084-EB490B394DE4

P2860

Q34549516-06FE4913-49D0-4B57-8FC3-7282209E1FD5

Q34549516-0AE7A3CE-8276-4E9C-9FD0-6EE01521CD50

Q34549516-0D95F097-59F9-42DC-9C59-F9E01A53CE8C

Q34549516-0DB40019-814E-474F-85CF-9D6E007B4D9F

Q34549516-173BE231-F30A-4934-8A9A-971FD1EA6ABD

Q34549516-1BC62CDE-55E9-44A2-89B5-D11738C5B759

Q34549516-22F7015A-E328-4C33-AB5F-B20C5D7717FE

Q34549516-26560A5A-0C35-48C3-93E9-5DC6E367ADE1

Q34549516-2B181629-D475-4909-86D7-6890D5CC150A

Q34549516-2D37364E-1264-408E-89BC-9C43519E740F

P304

Q34549516-B651C26C-D256-4EF0-9409-75227A7CD304

P31

Q34549516-7B34893B-1AB9-4E5A-9E2B-F359C538C403

P356

Q34549516-15981058-5BC7-444B-97EF-D66C1985CFCE

P407

Q34549516-EF980BE6-5942-4C9C-9F08-1589A6D02EE9

P433

Q34549516-384A9B95-B929-42C6-8100-15BE17D185B6

P478

Q34549516-94A419B6-2617-4351-94E0-803A4A1B9E91

P50

Q34549516-494FDD11-C956-425E-A4AA-5D0394F729C8

Q34549516-A95DE820-778D-4111-9717-E7323E0F6A79

Q34549516-ABCDDF98-81DB-4F68-8D5C-A2BDCFF2F6A3

Q34549516-D8CB328E-AA05-44B1-AD4B-B90B42FC0741

Q34549516-E341CF6F-8273-494E-89DC-3EE1D6EF18CE

Q34549516-F79DA37A-9CF1-4F8F-B9EF-013931383000

P577

Q34549516-3472C278-BA4F-41B6-BA04-10AEC321A6BA

P698

Q34549516-7F25F473-C8FA-49BE-BE52-ED59BE951C3E

P932

Q34549516-80ABA2FC-E84D-4B27-8955-36F3057E595A

P356

2159-8290.CD-14-0623

P1433

Cancer Discovery

P1476

Somatic ERCC2 mutations correl ...... -invasive urothelial carcinoma

@en

P2093

Alan D'Andrea

http://www.w3.org/2001/XMLSchema#string

Angela Qu

http://www.w3.org/2001/XMLSchema#string

Cong Zhu

http://www.w3.org/2001/XMLSchema#string

David B Solit

http://www.w3.org/2001/XMLSchema#string

Dean F Bajorin

http://www.w3.org/2001/XMLSchema#string

Deborah Farlow

http://www.w3.org/2001/XMLSchema#string

Eliezer M Van Allen

http://www.w3.org/2001/XMLSchema#string

Elizabeth A Guancial

http://www.w3.org/2001/XMLSchema#string

Gad Getz

http://www.w3.org/2001/XMLSchema#string

Gopa Iyer

http://www.w3.org/2001/XMLSchema#string

P2860

DNA Damage, Aging, and Cancer

A landscape of driver mutations in melanoma

Mutational heterogeneity in cancer and the search for new cancer-associated genes

Genome sequencing identifies a basis for everolimus sensitivity

A novel high-throughput (HTP) cloning strategy for site-directed designed chimeragenesis and mutation using the Gateway cloning system.

Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients.

Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.

The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data

A method and server for predicting damaging missense mutations

A summary of mutations in the UV-sensitive disorders: xeroderma pigmentosum, Cockayne syndrome, and trichothiodystrophy

P304

1140-1153

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/2159-8290.CD-14-0623

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

Philip W. Kantoff

Jonathan E Rosenberg

Hikmat Al-Ahmadie

Bernard H Bochner

Levi A Garraway

P577

2014-08-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25096233

http://www.w3.org/2001/XMLSchema#string

P932

4238969

http://www.w3.org/2001/XMLSchema#string